Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463072 · ClinicalTrials.gov registry record · Phase 2
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT01463072: Active Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma, sponsored by City of Hope Medical Center.
NCT01463072 is a Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 40 participants, below the 164-participant average among 32 other Metastatic Breast Carcinoma trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01463072, a Phase 2 study of Metastatic Breast Carcinoma and Recurrent Breast Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Primary Outcome
Will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Rates and associated 95% exact Clopper and Pearson binomial confidence limits will be estimated for grade 2 or higher toxicities attributed to treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Nab-paclitaxel
Study Locations (4)
California
- City of Hope medical - Duarte
- City of Hope Antelope Valley - Lancaster
- City of Hope South Pasadena - South Pasadena
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2026-05-18 |
| Phase | Phase 2 |
What the registry record for NCT01463072 still lists
NCT01463072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 164-participant average among 32 other Metastatic Breast Carcinoma trials with a reported enrollment target (76% lower).
The record links to 8 conditions, with Metastatic Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01463072 reports a single indexed study location in California, Ohio.
Frequently Asked Questions
What is clinical trial NCT01463072 about?
NCT01463072 is a clinical study titled "Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer". This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work ...
What is the current status of trial NCT01463072?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-06-19. Estimated completion is 2026-05-18.
What conditions does trial NCT01463072 study?
This clinical trial studies the following conditions: Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7.
What interventions are being tested in trial NCT01463072?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01463072?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01463072 being conducted?
This trial has 4 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01463072's enrollment target sits among peer trials
40 17th of 32 higher than 15 of 32 other Metastatic Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
RECRUITING · Phase 2
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI